BLAINJECTIONINJECTABLEPriority Review
Approved
Dec 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
37
Data completeness
4/8 — Partial
Priority Review
ULTOMIRIS (ravulizumab) by AstraZeneca is complement inhibitors [moa]. First approved in 2018.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ULTOMIRIS (ravulizumab) is a monoclonal antibody that inhibits the complement C5 protein, blocking a key pathway in the complement cascade. It is administered intravenously and is used to treat rare hemolytic conditions mediated by complement dysregulation. The drug prevents terminal complement-mediated cell lysis and inflammation in patient populations with severe, life-threatening hemolytic disease.
$160MPart D
PeakULTOMIRIS is at peak commercial maturity with established market presence; career opportunities focus on defending market position against newer entrants and optimizing existing patient base management.
Mechanism of Action
Complement Inhibitors
Pharmacologic Class:
Complement Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (37)
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
Started Jul 2026
20 enrolled
Generalized Myasthenia GravisgMG
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Started Jul 2026
19 enrolled
NMOSDNeuromyelitis Optica Spectrum Disorder
Ravulizumab Outcomes in Polish Patients With aHUS
Started Jun 2026
80 enrolled
Atypical Hemolytic Uremic Syndrome
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
Started Mar 2026
75 enrolled
Generalized Myasthenia GravisgMG
Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab
Started Jan 2026
24 enrolled
Myasthenia Gravis Generalised
Worked on ULTOMIRIS at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.